Researchers report increasing trends in psychotropic medication use to treat problem behavior in individuals with intellectual and developmental disability, despite some controversy regarding its application and treatment efficacy. A substantial evidence base exists supporting behavioral intervention efficacy, however research evaluating separate and combined intervention (i.e., concurrent application of behavioral and psychopharmacological interventions) effects remains scarce. This article demonstrates how a series of analyses on clinical data collected during treatment (i.e., four case studies) may be used to retrospectively explore separate and combined intervention effects on severe problem behavior. First, we calculated individual effect sizes and corresponding confidence intervals. The results indicated larger problem behavior decreases may have coincided more often with behavioral intervention adjustments compared to medication adjustments. Second, a conditional rates analysis indicated surges in problem behavior did not reliably coincide with medication reductions. Spearman correlation analyses indicated a negative relationship between behavioral intervention phase progress and weekly episodes of problem behavior compared to a positive relationship between total medication dosage and weekly episodes of problem behavior. However, a nonparametric partial correlation analyses indicated individualized, complex relationships may exist among total medication dosage, behavioral intervention, and weekly episodes of problem behavior. We discuss potential clinical implications and encourage behavioral researchers and practitioners to consider applying creative analytic strategies to evaluate separate and combined intervention effects on problem behavior to further explore this extremely understudied topic.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Allington-Smith, P. (2006). Mental health of children with learning disabilities. Advances in Psychiatric Treatment, 12(2), 130–138. https://doi.org/10.1192/apt.12.2.130.
Bakaki, P. M., Horace, A., Dawson, N., Winterstein, A., Waldron, J., Staley, J., et al. (2018). Defining pediatric polypharmacy: A scoping review. PLOS ONE, 13(11), 1–23. https://doi.org/10.1371/journal.pone.0208047.
Beavers, G. A., Iwata, B. A., & Lerman, D. C. (2013). Thirty years of research on the functional analysis of problem behavior. Journal of Applied Behavior Analysis, 46(1), 1–21. https://doi.org/10.1002/jaba.30.
Berigan, T. R., & Harazin, J. S. (1999). Bupropion-associated withdrawal symptoms: A case report. Primary Care Companion to the Journal of Clinical Psychiatry, 1(2), 50–51.
Blenkush, N. A., & O’Neil, J. (2020). Contingent skin-shock treatment in 173 cases of severe problem behavior. International Journal of Psychology & Behavior Analysis, 6, 167. https://doi.org/10.15344/2455-3867/2020/167.
Bezchlibnyk-Butler, K., Aleksic, I., & Kennedy, S. (2000). Citaloprami: A review of pharmacological and clinical effects. Journal of Psychiatry & Neuroscience, 25(3), 241 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407724/pdf/jpn00086-0027.pdf.
Cox, A. D., & Virues-Ortega, J. (2016). Interactions between behavior function and psychotropic medication. Journal of Applied Behavior Analysis, 49(1), 85–104. https://doi.org/10.1002/jaba.247.
Deb, S., Unwin, G., & Deb, T. (2015). Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behavior. Journal of Intellectual Disability Research, 59(1), 11–25. https://doi.org/10.1111/jir.12119.
de Kuijper, G. M., & Hoekstra, P. J. (2017). Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability. Journal of Intellectual Disability Research, 61(10), 899–908. https://doi.org/10.1111/jir.12385.
Derby, K. M., Wacker, D. P., Sasso, G., Steege, M., Northup, J., Cigrand, K., & Asmus, J. (1992). Brief functional assessment techniques to evaluate aberrant behavior in an outpatient setting: A summary of 79 cases. Journal of Applied Behavior Analysis, 25(3), 713–721. https://doi.org/10.1901/jaba.1992.25-713.
Du Prel, J. B., Hommel, G., Röhrig, B., & Blettner, M. (2009). Confidence interval or p-value? Deutsches Ärzteblatt International, 106(19), 335–339.
Durlak, J. A. (2009). How to select, calculate, and interpret effect sizes. Journal of Pediatric Psychology, 34(9), 917–928. https://doi.org/10.1093/jpepsy/jsp004.
Field, A. (2018). Discovering statistics using IBM SPSS Statistics (5th ed.). Thousand Oaks: Sage.
Garcia, D., & Smith, R. G. (1999). Using analog baselines to assess the effects of naltrexone on self-injurious. Research in Developmental Disabilities, 20(1), 1–21. https://doi.org/10.1016/S0891-4222(98)00028-6.
Gierut, J. A., Morrisette, M. L., & Dickinson, S. L. (2015). Effect size for single-subject design in phonological treatment. Journal of Speech, Language, & Hearing Research, 58(5), 1464–1481. https://doi.org/10.1044/2015_JSLHR-S-14-0299.
Hagopian, L. P. (2020). The consecutive controlled case series: Design, data-analytics, and reporting methods supporting the study of generality. Journal of Applied Behavior Analysis, 53(2), 596–619. https://doi.org/10.1002/jaba.691.
Hanley, G. P., Iwata, B. A., & Roscoe, E. M. (2006). Some determinants of changes in preference over time. Journal of Applied Behavior Analysis, 39(2), 189–202. https://doi.org/10.1901/jaba.2006.163-04.
Hysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., et al. (2013). Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. International Journal of Neuropsychopharmacology, 17(3), 371–381. https://doi.org/10.1017/s1461145713001132.
Ji, N. Y., & Findling, R. L. (2016). Pharmacotherapy for mental health problems in people with intellectual disability. Current Opinion in Psychiatry, 29(2), 103–125. https://doi.org/10.1097/YCO.0000000000000233.
Li, A., & Poling, A. (2018). Board certified behavior analysts and psychotropic medications: Slipshod training, inconsistent involvement, and reason for hope. Behavior Analysis in Practice, 11(4), 350–357. https://doi.org/10.1007/s40617-018-0237-9.
Lloyd, B. P., Torelli, J. N., & Symons, F. J. (2016). Issues in integrating psychotropic and intensive behavioral interventions for students with emotional and behavioral challenges in schools. Journal of Emotional & Behavioral Disorders, 24(3), 148–158. https://doi.org/10.1177/1063426616636346.
Lunsky, Y., Khuu, W., Tadrous, M., Vigod, S., Cobigo, V., & Gomes, T. (2018). Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. Canadian Journal of Psychiatry, 63(6), 361–369. https://doi.org/10.1177/0706743717727240.
Maan, J. S., Ershadi, M., & Saadabadi, A. (2020). Quetiapine. Treasure Island: StatPearls Publishing Retrieved November 24, 2020, from https://www.ncbi.nlm.nih.gov/books/NBK459145/.
Matson, J. L., & Neal, D. (2009). Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities, 30(3), 572–586. https://doi.org/10.1016/j.ridd.2008.08.007.
McComas, J. J., Moore, T., Dahl, N., Hartman, E., Hoch, J., & Symons, F. (2009). Calculating contingencies in natural environments: Issues in the application of sequential analysis. Journal of Applied Behavior Analysis, 42(2), 413–423. https://doi.org/10.1901/jaba.2009.42-413.
McKerchar, P. M., & Thompson, R. H. (2004). A descriptive analysis of potential reinforcement contingencies in the preschool classroom. Journal of Applied Behavior Analysis, 37(4), 431–444. https://doi.org/10.1901/jaba.2004.37-431.
Ombudsman Ontario, & Dube, P. (2016, August). Nowhere to turn: Investigation into the Ministry of Community and Social Services’ response to situations of crisis involving adults with developmental disabilities. Ombudsman Ontario. Retrieved from https://www.ombudsman.on.ca/Media/ombudsman/ombudsman/resources/Reports-on-Investigations/NTT-Final-EN-w-cover.pdf
Poling, A., Ehrhardt, K., & Li, A. (2017). Psychotropic medications as treatments for people with autism spectrum disorder. In J. L. Matson (Ed.), Handbook of treatments for autism spectrum disorder (pp. 459–476). New York: Springer. https://doi.org/10.1007/978-3-319-61738-1_25.
Pritchard, D., Hoerger, M., Dyer, T., Graham, N., Penney, H., & Mace, F. C. (2013). Sodium valproate withdrawal correlates with reduced aggression. British Journal of Learning Disabilities, 42, 162–167. https://doi.org/10.1111/bld.12019.
Pritchard, D., Penney, H., & Mace, F. C. (2017). The ACHIEVE! program: A point and level system for reducing severe problem behavior. Behavioral Interventions, 31(2), 41–55. https://doi.org/10.1002/bin.1506.
Pritchard, D., Penney, H., Richards, V., & Graham, N. (in press). Behavioral treatment of sexual offending. In J. K. Luiselli (Ed.), Applied behavior analysis treatment of violence and aggression in persons with neurodevelopmental disabilities. New York: Springer.
Rapp, J. T., Swanson, G., & Dornbusch, K. (2007). Temporary increases in problem behavior and sleep disruption following decreases in medication: A descriptive analysis of conditional rates. Behavior Modification, 31(6), 825–846. https://doi.org/10.1177/0145445507301653.
Ruble, L. A., Heflinger, C. A., Renfrew, J. W., & Saunders, R. C. (2005). Access and Service Use by Children with Autism Spectrum Disorders in Medicaid Managed Care. Journal of Autism and Developmental Disorders, 35(1), 3–13. https://doi.org/10.1007/s10803-004-1026-6.
Spencer, D., Marshall, J., Post, B., Kulakodlu, M., Newschaffer, C., Dennen, T., et al. (2013). Psychotropic medication use and polypharmacy in children with autism. Pediatrics, 132(5), 833–840.
Valdovinos, M. G. (2019). Psychotropic medication in intellectual and developmental disabilities: Patterns of use and recommendations for monitoring effects. Current Developmental Disorders Reports, 6, 195–201. https://doi.org/10.1007/s40474-019-00179-5.
Valdovinos, M. G., Caruso, M., Roberts, C., Kim, G., & Kennedy, C. H. (2005). Medical and behavioral symptoms as potential medication side effects in adults with developmental disabilities. American Journal on Mental Retardation, 110(3), 164–170. https://doi.org/10.1352/0895-8017(2005)110%3C164:MABSAP%3E2.0.CO;2.
Valdovinos, M. G., Henninger-McMahon, M., Schieber, E., Beard, L., Conley, B., & Haas, A. (2016). Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. International Journal of Developmental Disabilities, 62(3), 200–211. https://doi.org/10.1080/20473869.2016.1177301.
Valdovinos, M. G., Nelson, S. M., Kuhle, J. L., & Dierks, A. M. (2009). Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: A clinical demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2(4), 279–293. https://doi.org/10.1080/19315860903104807.
Valdovinos, M. G., Schieber, E., McMahon, M., Beard, L., Wilkinson, A., & Carpenter, J. (2017). Adverse side effects of psychotropic medication and challenging behavior: Pilot work assessing impact. Journal of Developmental & Physical Disabilities, 29(6), 969–982. https://doi.org/10.1007/s10882-017-9570-0.
van Haaren, F., & Weeden, M. (2013). Some guidelines for conducting research in applied behavioral pharmacology. Journal of Applied Behavior Analysis, 46(2), 498–506. https://doi.org/10.1002/jaba.47.
Verriden, A. L., & Roscoe, E. M. (2016). A comparison of preference-assessment methods. Journal of Applied Behavior Analysis, 49(2), 265–285. https://doi.org/10.1002/jaba.302.
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., et al. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience, 21(2), 1–5. https://doi.org/10.1523/jneurosci.21-02-j0001.2001.
Wachtel, L. E., & Hagopian, L. P. (2006). Psychopharmacology and applied behavioral analysis: Tandem treatment of severe problem behaviors in intellectual disability and a case series. Israel Journal of Psychiatry & Related Sciences, 43(4), 265–274.
Wolf, M. M. (1978). Social validity: The case for subjective measurement or how applied behavior analysis is finding its heart. Journal of Applied Behavior Analysis, 11(2), 203–214. https://doi.org/10.1901/jaba.1978.11-203.
Yu, G., Li, G.-F., & Markowitz, J. S. (2016). Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. Journal of Child & Adolescent Psychopharmacology, 26(4), 314–326. https://doi.org/10.1089/cap.2015.0137.
Zabegalov, K. N., Kolesnikova, T. O., Khatsko, S. L., Volgin, A. D., Yakovlev, O. A., Amstislavskaya, T. G., et al. (2018). Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. European Journal of Pharmacology, 829, 129–140. https://doi.org/10.1016/j.ejphar.2018.04.00.
Zarcone, J. R., Lindauer, S. E., Morse, P. S., Crosland, K. A., Valdovinos, M. G., McKerchar, T. L., et al. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal on Mental Retardation, 109(4), 310–321. https://doi.org/10.1352/0895-8017(2004)109%3C310:EORODB%3E2.0.CO;2.
Conflict of Interests
We have no known conflict of interests to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cox, A.D., Pritchard, D., Penney, H. et al. Demonstrating an Analyses of Clinical Data Evaluating Psychotropic Medication Reductions and the ACHIEVE! Program in Adolescents with Severe Problem Behavior. Perspect Behav Sci (2021). https://doi.org/10.1007/s40614-020-00279-3
- The ACHIEVE! program
- Psychopharmacological interventions
- Severe problem behavior
- Adolescents with intellectual and developmental disability